Skip to content
    Agent Capital logo

    Agent Capital

    Waltham, Massachusetts, United StatesFounded 2016
    www.agentcapital.comLinkedIn
    HealthcareBiotech & Life Sciences

    Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs. The firm invests across all stages of development, from early-stage seed rounds to later-stage crossover and PIPE financings.

    50% of their portfolio is in Biotech & Life Sciences. They made 2 investments in the last 12 months. Average disclosed round size is $54.6M (across 36 rounds with reported amounts).

    Find people at Agent Capital on Goldilocks AI

    Portfolio

    34

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    1

    Team

    PN

    Preston Noon, PharmD, MBA

    Partner, Co-Founder

    GV

    Geeta Vemuri, PhD, MBA

    Managing Partner, Founder

    BP

    Bruce Peacock

    Operating Partner

    JG

    John Glasspool

    Venture Partner

    JO

    John Orloff, MD

    Venture Partner

    AD

    Anthony DiNatale, PhD

    Vice President

    LK

    Lisa Kraeutler

    VP of Fund Finance

    MM

    Marla McMillan, MBA

    VP of Fund Finance

    KN

    Kirti Nimmala, MS

    Investment Associate

    VA

    Venkata Aditya Kalaga, MTM

    Investment Analyst

    JG

    Julie Gionfriddo

    Head of Investor Relations and Fundraising

    LF

    Lori Forrest, CPA

    Controller

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    42 investments
    CompanyRoundAmountDate
    The General Intelligence Company logoThe General Intelligence CompanySeed$8.7MDec 2025
    Composio logoComposioSeries A$29MJul 2025
    Star Therapeutics logoStar TherapeuticsSeries D$125MJan 2025
    Weave logoWeaveSeries A—Jan 2025
    Weave logoWeaveSeries A—Jan 2025
    HONE HEALTH logoHONE HEALTHSeries A$33MJan 2025
    Cerevance logoCerevanceSeries C$51MApr 2024
    VVittoriaSeed$25MJan 2024
    Foresight Diagnostics logoForesight DiagnosticsSeries B$58.8MApr 2023
    ViTToria Biotherapeutics logoViTToria BiotherapeuticsSeries A$15MJan 2023
    Carbon Biosciences logoCarbon BiosciencesSeries A$38MJun 2022
    ImCheck logoImCheckSeries C—Jun 2022
    Immunitas Therapeutics logoImmunitas TherapeuticsSeries B$58MAug 2021
    IImmunitasSeries B$58MAug 2021
    Interius BioTherapeutics logoInterius BioTherapeuticsSeries A$76MMay 2021
    CCarisma Therapeutics, Inc.Series B—Mar 2021
    IImmunitasSeries B$58MJan 2021
    Entrada logoEntradaSeries B$116MJan 2021
    PPalvella Therapeutics, Inc.Series C$45MMay 2020
    IImCheck TherapeuticsSeries C—Dec 2019
    Pyxis Oncology logoPyxis OncologySeries A$22MJul 2019
    Immunitas Therapeutics logoImmunitas TherapeuticsSeries A$39MJan 2019
    EEntrada TherapeuticsSeries A$59MDec 2018
    Orchard Therapeutics logoOrchard TherapeuticsSeries C$150MAug 2018
    Verge Genomics logoVerge GenomicsSeries A—Jul 2018
    Page 1 of 2

    Top Co-Investors

    Alexandria Venture Investments8 shared
    MRL Ventures Fund8 shared
    Wellington Management6 shared
    Solasta Ventures6 shared
    Longwood Fund5 shared
    Cormorant Asset Management5 shared
    RA Capital Management5 shared
    TPG Biotech4 shared
    HealthCap4 shared
    BrightEdge4 shared
    Osage University Partners4 shared
    Pfizer Ventures4 shared
    Cowen Healthcare Investments4 shared
    Roche Venture Fund4 shared
    MPM Capital4 shared
    Y Combinator3 shared
    Leaps by Bayer3 shared
    New Leaf Venture Partners3 shared
    Redmile Group3 shared
    Mirae Asset3 shared

    Last updated: 8 September 2026